Skip to main content
Clinical Trials/ACTRN12616000272493
ACTRN12616000272493
Active, not recruiting
未知

A longitudinal, observational study investigating pigmentation genotypes and phenotypic correlations with dermoscopic naevus types and distribution in two participant groups; advanced stage melanoma patients undergoing targeted and/or immunotherapies, and a 'high risk' melanoma patient group.

The University of Queensland0 sites170 target enrollmentMarch 1, 2016

Overview

Phase
未知
Intervention
Not specified
Conditions
Melanoma
Sponsor
The University of Queensland
Enrollment
170
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 1, 2016
End Date
TBD
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Cohort 1: melanoma patients with stage III and IV enrolled for treatment with targeted therapies and/or immunotherapies at the Cancer Services (PA Hospital). Baseline visit must be within 6 weeks of beginning melanoma treatment.
  • Cohort 2: participants considered high risk for melanoma under at least one of the following three subcategories;
  • a)Personal history of melanoma (stage I\-IV, not in situ)
  • b)First degree family history of melanoma (stage I\-IV, not in situ)
  • c)Atypical mole syndrome, defined as grater then 100 naevi, 6 (or more) atypical naevi (confirmed using dermoscopy), AND at least 1 naevus 8 mm (or greater) in dimension.

Exclusion Criteria

  • All participants must be able to give informed consent.
  • All participants are asked to commit to 4 visits to the PA Hospital to participate in the trial over a 12 month period (months 0, 4, 8 and 12\), as long as they are able to (Participants can withdraw from the study at any time for any reason).
  • Participants in cohort 2 must not be currently undergoing any treatment for melanoma.

Outcomes

Primary Outcomes

Not specified

Similar Trials